drugset
drugset / Trial / NCT02420873

An Open-label Phase II Study of Lorvotuzumab Mertansine

NCT02420873 ↗

Phase 2 Completed 9 enrolled M.D. Anderson Cancer Center ImmunoGen, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if lorvotuzumab mertansine can help to control blood cancers that have the CD56 tumor marker. The safety of this drug will also be studied.

Timeline

Start
2015-05-12
Primary completion
2017-06-06
Completion
2017-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorvotuzumab Mertansine Monoclonal antibody 100 mg/m2 Intravenous

Indications

leukemia